Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 84, Issue 5, pp 987–992 | Cite as

Optimal dose of sunitinib for long-term treatment in Japanese patients with renal cell carcinoma

  • Yuto Yamada
  • Yuta Ohno
  • Yu Kato
  • Ryo Kobayashi
  • Hideki Hayashi
  • Shiho Miyahara
  • Keita Nakane
  • Kosuke Mizutani
  • Shigeaki Yokoi
  • Hironori Fujii
  • Hirotoshi Iihara
  • Takuma Ishihara
  • Takashi Deguchi
  • Tadashi Sugiyama
  • Akio SuzukiEmail author
Original Article
  • 135 Downloads

Abstract

Background/aim

Sunitinib is used for the treatment of metastatic renal cell carcinoma (mRCC). Asian patients, including Japanese, tend not to tolerate long-term sunitinib therapy of 50 mg p.o. once daily for 4 weeks, followed by 2 week off treatment due to severe adverse events at this dosage level. The aim of this retrospective study was to investigate the optimal dose of sunitinib for long-term continuation in Asian patients with mRCC.

Patients and methods

The study cases were 50 patients with mRCC who were treated with sunitinib between June 2008 and December 2017. Risk analysis for “unacceptable” adverse events (depending on the physician, ranging from grade 2 to ≥ grade 3) leading to discontinuation of sunitinib was determined by time-dependent Cox proportional hazard regression analysis.

Results

A total of 54 unacceptable adverse events leading to discontinuation occurred. Multivariable analysis indicated that a sunitinib dose of ≤ 37.5 mg/day significantly reduced the risk of discontinuation due to adverse events in comparison with 50 mg/day [hazard ratio (HR) 0.08, 95% confidence interval (CI) 0.03–0.21, p < 0.001). The progression-free survival (PFS) with a sunitinib dose ≤ 37.5 mg/day was longer than that associated with a dose of 50 mg/day, albeit not to a statistically significant degree (120 days for ≤ 37.5 mg/day vs 41 days for 50 mg/day, HR 0.39, 95% CI 0.10–1.44, p = 0.157).

Conclusion

Our findings suggest that the optimal dose of sunitinib for Asian, including Japanese, patients with mRCC is ≤ 37.5 mg/day.

Keywords

Sunitinib Metastatic renal cell carcinoma Adverse events Asian patients 

Notes

Acknowledgements

We thank Libby Cone, MD, MA, from DMC Corp. (www.dmed.co.jp <http://www.dmed.co.jp/>) for editing a draft of this manuscript.

Funding

This study did not receive funding from any funding source.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337PubMedPubMedCentralGoogle Scholar
  2. 2.
    Miyake H, Miyazaki A, Harada K, Fujisawa M (2014) Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. Med Oncol 31:978CrossRefPubMedGoogle Scholar
  3. 3.
    Cella D, Cappelleri JC, Bushmakin A, Charbonneau C, Li JZ, Kim ST, Chen I, Michaelson MD, Motzer RJ (2009) Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa. J Oncol Pract 5:66–70CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Hershey AD, Investigators CHAMP (2017) Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med 376:115–124CrossRefPubMedGoogle Scholar
  5. 5.
    Liu X, Fiocco M, Swen JJ, Guchelaar HJ (2017) Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis. Acta Oncol 56:582–589CrossRefPubMedGoogle Scholar
  6. 6.
    Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H (2010) A Phase II study of sunitinib in japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 40:194–202CrossRefPubMedGoogle Scholar
  7. 7.
    Tomita Y, Shinohara N, Yuasa T, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Uemura H, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H (2010) Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 40:1166–1172CrossRefPubMedGoogle Scholar
  8. 8.
    US Department of Health and Human Services. National Institutes of Health National Cancer Institute (2009) Common terminology criteria for adverse events (CTCAE) Version 4.0. https://www.eortc.be/services/doc/ctc/; Accessed 24 March 2019
  9. 9.
    Akaza H, Naito S, Ueno N, Aoki K, Houzawa H, Pitman Lowenthal S, Lee SY (2015) Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients. Jpn J Clin Oncol 45:576–583CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kawashima A, Tsujimura A, Takayama H, Arai Y, Nin M, Tanigawa G, Yasunaga Y, Mukai M, Uemura M, Nakai Y, Nishimura K, Nonomura N, Osaka Renal Cell Carcinoma Clinical Study Collaboration (2012) Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma. Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma. Med Oncol 29:3298–3305CrossRefPubMedGoogle Scholar
  11. 11.
    Nagata M, Ishiwata Y, Takahashi Y, Takahashi H, Saito K, Fujii Y, Kihara K, Yasuhara M (2015) Pharmacokinetic-pharmacodynamic analysis of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma. Biol Pharm Bull 38:402–410CrossRefPubMedGoogle Scholar
  12. 12.
    Teo YL, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A (2015) Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. Target Oncol 10:429–437CrossRefPubMedGoogle Scholar
  13. 13.
    Mizuno M, Iizuka K, Ishihara T, Fukaya S, Yoshida S, Takeda J (2019) High dose prednisolone lowers plasma glycated albumin levels compared to actual glycemic control: a retrospective observational study. Diabetes Ther 10:269–276CrossRefPubMedGoogle Scholar
  14. 14.
    Simon R, Makuch RW (1984) A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus nonresponder bias. Stat Med 3:35–44CrossRefPubMedGoogle Scholar
  15. 15.
    Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K, Okada Y, Kawauchi A, Onishi H, Hira D, Morita SY, Terada T (2015) Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma. Clin Genitourin Cancer 13:350–358CrossRefPubMedGoogle Scholar
  16. 16.
    Takasaki S, Kawasaki Y, Kikuchi M, Tanaka M, Suzuka M, Noda A, Sato Y, Yamashita S, Mitsuzuka K, Saito H, Ito A, Yamaguchi H, Arai Y, Mano N (2018) Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma. Int J Clin Oncol 23:936–943CrossRefPubMedGoogle Scholar
  17. 17.
    Ruiz-Morales JM, Swierkowski M, Wells JC, Fraccon AP, Pasini F, Donskov F, Bjarnason GA, Lee JL, Sim HW, Sliwczynsk A, Ptak-Chmielewska A, Teter Z, Beuselinck B, Wood LA, Yuasa T, Pezaro C, Rini BI, Szczylik C, Choueiri TK, Heng DY (2016) First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Eur J Cancer 65:102–108CrossRefPubMedGoogle Scholar
  18. 18.
    Lakomy R, Poprach A, Bortlicek Z, Melichar B, Chloupkova R, Vyzula R, Zemanova M, Kopeckova K, Svoboda M, Slaby O, Kiss I, Studentova H, Juracek J, Fiala O, Kopecky J, Finek J, Dusek L, Hejduk K, Buchler T, Lakomy R, Poprach A, Bortlicek Z, Melichar B, Chloupkova R, Vyzula R, Zemanova M, Kopeckova K, Svoboda M, Slaby O, Kiss I, Studentova H, Juracek J, Fiala O, Kopecky J, Finek J, Dusek L, Hejduk K, Buchler T (2017) Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. BMC Cancer 17:880CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Takahito N, Kei N, Hidenori I, Nobuki F, Kenichi T, Motonobu N (2018) Efficacy and safety of third- and fourth-line targeted therapy in Japanese patients with metastatic renal cell carcinoma: a retrospective analysis. Indian J Urol 34:127–132CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Mizuno T, Terada T, Kamba T, Fukudo M, Katsura T, Nakamura E, Ogawa O, Inui K (2010) ABCG2 421C > A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann Oncol 21:1382–1383CrossRefPubMedGoogle Scholar
  21. 21.
    Mizuno T, Fukudo M, Terada T, Kamba T, Nakamura E, Ogawa O, Inui K, Katsura T (2012) Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. Drug Metab Pharmacokinet 27:631–639CrossRefPubMedGoogle Scholar
  22. 22.
    Mizuno T, Fukudo M, Fukuda T, Terada T, Dong M, Kamba T, Yamasaki T, Ogawa O, Katsura T, Inui K, Vinks AA, Matsubara K (2014) The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma. Ther Drug Monit 36:310–316CrossRefPubMedGoogle Scholar
  23. 23.
    Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K, Okada Y, Kawauchi A, Onishi H, Hira D, Morita SY, Terada T (2015) Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma. Clin Genitourin Cancer 13:350–358CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Yuto Yamada
    • 1
    • 2
  • Yuta Ohno
    • 1
  • Yu Kato
    • 2
  • Ryo Kobayashi
    • 1
  • Hideki Hayashi
    • 1
    • 2
  • Shiho Miyahara
    • 2
  • Keita Nakane
    • 3
  • Kosuke Mizutani
    • 3
  • Shigeaki Yokoi
    • 3
  • Hironori Fujii
    • 1
  • Hirotoshi Iihara
    • 1
    • 2
  • Takuma Ishihara
    • 4
  • Takashi Deguchi
    • 3
  • Tadashi Sugiyama
    • 2
  • Akio Suzuki
    • 1
    • 2
    Email author
  1. 1.Department of PharmacyGifu University HospitalGifuJapan
  2. 2.Laboratory of Pharmacy Practice and Social ScienceGifu Pharmaceutical UniversityGifuJapan
  3. 3.Department of Urology, Graduate School of MedicineGifu UniversityGifuJapan
  4. 4.Gifu University Hospital Innovative and Clinical Research Promotion CenterGifu UniversityGifuJapan

Personalised recommendations